18 recruiting, 17 completed, 7 terminated, 6 unknown. 19 Phase 1, 19 Phase 2, 14 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Ovary Cancer: new trials by email Literature Review of Ovary Cancer trials Research Report on Ovary Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness - Breast Cancer, Corpus Uteri Cancer | Not applicable | Recruiting | University of Alabama at Birmingham | 2748 | 2026-10-02 | 2026-10-07 |
| Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies Gynecologic Cancer, Cervical Cancer | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 160 | 2026-08-01 | 2026-07-14 | |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer Sunitinib、Olaparib、Tolilizumab - Ovary Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 35 | 2026-06-01 | 2026-06-25 |
| ICRA Randomised Controlled Trial delayed cytoreduction surgery, interval cytoreduction surgery - Ovary Cancer | Phase 3 | Not yet recruiting | NHS Grampian | 682 | 2026-01-31 | 2025-07-16 |
| An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer METR-NK cell（metabolic remodeling nature killer cells） - Ovary Cancer | Phase 1 / Phase 2 | Active not recruiting | Anhui Provincial Cancer Hospital | 20 | 2025-07-07 | 2025-07-31 |
| No-Stoma Policy in Advanced Ovarian Cancer Surgery colon-rectal resection - Ovary Cancer | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 395 | 2025-05-01 | 2025-10-08 |
| GYNecologic Cancer-Related COGnitive Impairment GYNCOG - Ovarian Cancer, Endometrial Cancer | Not applicable | Completed | Northwestern University | 60 | 2025-02-07 | 2026-03-23 |
| Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer Senaparib, Temozolomide - Ovary Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2025-02-06 | 2025-10-27 |
| Multimedia Aid for Genetic Testing in Gynecologic Oncology Educational videos, Survey - Ovary Cancer, Endometrial Cancer | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 30 | 2024-10-10 | 2025-11-12 |
| RC48 in Combination With AK104 and Bevacizumab in OCCC Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer - Ovary Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 | 2024-09-24 | 2026-08-27 |
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Tart Cherry Juice - Breast Cancer, Breast Cancer Stage I | Phase 2 | Recruiting | University of California, Davis | 86 | 2024-08-15 | 2026-03-04 |
| The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women FRD001 - Ovary Cancer | Not applicable | Recruiting | Tongji Hospital | 198 | 2024-07-01 | 2024-08-16 |
| SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours Blood test, Pathology specimen miRNA expression - Germ Cell Ovarian Cancer, Germ Cell Tumor | Not yet recruiting | Imperial College London | 24 | 2024-04-14 | 2024-03-26 | |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors UCMYM802 Injection - Malignant Mesothelioma, Colorectal Cancer | Phase 1 | Unknown | UTC Therapeutics Inc. | 24 | 2024-03-05 | 2024-07-24 |
| Mesenteric Infiltration in Ovarian Cancer Computed Tomography - Ovary Cancer | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 510 | 2024-03-01 | 2025-03-12 | |
| Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy FAST Intervention - Ovary Cancer, Endometrial Cancer | Not applicable | Recruiting | Northwestern University | 30 | 2023-10-16 | 2026-10-15 |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib Mirvetuximab Soravtansine-gynx, Olaparib - Ovary Cancer, Peritoneal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 53 | 2023-10-03 | 2026-07-13 |
| Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) Fit4Treatment - Ovary Cancer, Endometrial Cancer | Not applicable | Active not recruiting | Northwestern University | 192 | 2023-09-15 | 2026-10-19 |
| Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Carboplatin - Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Recruiting | University College, London | 80 | 2023-05-24 | 2024-04-12 |
Showing 20 of 56. Sign in to see all of them.
Ovarian Neoplasms (56) · Breast Neoplasms (16) · Endometrial Neoplasms (15) · Pancreatic Neoplasms (11) · Uterine Cervical Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (8) · Fallopian Tube Neoplasms (8) · Colorectal Neoplasms (7) · Esophageal Neoplasms (7) · Neoplasms (7) · Prostatic Neoplasms (7) · Lung Neoplasms (6) · Head and Neck Neoplasms (5) · Melanoma (5) · Uterine Neoplasms (5)
Adnexal Diseases (56) · Endocrine Gland Neoplasms (56) · Endocrine System Diseases (56) · Female Urogenital Diseases (56) · Female Urogenital Diseases and Pregnancy Complications (56) · Genital Diseases (56) · Genital Diseases, Female (56) · Genital Neoplasms, Female (56) · Gonadal Disorders (56) · Neoplasms by Site (56) · Urogenital Diseases (56) · Urogenital Neoplasms (56) · Ovarian Diseases (54) · Neoplasms (49) · Digestive System Diseases (20)
olaparib (4) · Carboplatin (3) · tisotumab vedotin (3) · Bevacizumab (2) · Exercise (2) · Paclitaxel (2) · Celecoxib (1) · Cisplatin (1) · Creatine Kinase, MM Form (1) · Cyclophosphamide (1) · Drug Therapy (1) · Folic Acid (1) · Hematologic Tests (1) · Immunotherapy (1) · Indocyanine Green (1)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (3) · Northwestern University (3) · Seagen Inc. (3) · Sutro Biopharma, Inc. (2) · University of Alabama at Birmingham (2) · Washington University School of Medicine (2) · A2 Biotherapeutics Inc. (1) · Aminex Therapeutics, Inc. (1) · Anhui Provincial Cancer Hospital (1) · AstraZeneca (1) · Bai-Rong Xia (1) · Boston Scientific Corporation (1) · CanariaBio Inc. (1) · Charite University, Berlin, Germany (1) · Cristiana Sessa (1)
United States (28) · China (8) · United Kingdom (8) · Italy (4) · Australia (3) · Denmark (3) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Hungary (1) · Israel (1) · Poland (1) · Spain (1) · Sweden (1)
Emma Barber, MD, MS (2) · Johann de Bono, Professor (2) · Aaron Weitzman, MD (1) · Alison Armour, MB ChB, BSc, MSc, MD, MRCP (1) · Anastasios Stathis, Prof. (1) · Anna Fagotti (1) · Anthony Greco, MD (1) · Arturo Molina, MD (1) · Bradley Corr, MD (1) · Camilla Panico, Dr (1) · Charlie Gourley, MD, PhD (1) · Christopher Nicodemus, MD FACP (1) · Clifford Robinson, M.D. (1) · Delphine Garbay, MD (1) · Domenica Lorusso, MD (1)
PMID 36459691, PMID 37496366, PMID 41044356, PMID 30745090, PMID 31796521, PMID 33188449, PMID 34612832, PMID 34757221, PMID 35046055, PMID 36971688, PMID 37208019, PMID 37434730, PMID 37883461, PMID 39448911, PMID 39806715, PMID 40659403, PMID 41707378, PMID 42567117, PMID 42658496
P01CA132714 (1), P01CA229997 (1)